Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLS31905 and/or QL1706 in CLDN18.2-positive advanced solid tumors
CTR20242328Phase 2Terminated
- Sponsor
- Qilu Pharmaceutical
- Start
- Jul 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of QLS-31905 in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, biliary cancer, Non-hematologic malignancy, sponsored by Qilu Pharmaceutical. Started Jul 2024; status: terminated.
02
Drugs
QLS-31905
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomabiliary cancerNon-hematologic malignancy
Beyond the preview
Go deeper on CTR20242328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242328.